Is the 4MGS a Useful Outcome Measure Post-PPCI

Acute Myocardial Infarction Clinical Trial

Official title:

Is the Four Metre Gait Speed a Useful Outcome Measure in Patients With Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02261324
• Other study ID #: 2013LF001H
• Status: Completed
• Start date: December 2013
• Est. completion date: January 2021

Study information

• Verified date: March 2021
• Source: Royal Brompton & Harefield NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to assess usual walking speed (4-metre gait speed) in patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial infarction and to assess whether this can predict future cardiovascular events and death.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 560
• Est. completion date: January 2021
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any patient hospitalised with an acute myocardial infarction who has undergone primary percutaneous coronary intervention

• Capacity to consent

• Able to walk

• Age over 18 years

Exclusion Criteria:

• Significant co-morbidities that would limit exercise capacity or make exercise unsafe (e.g. neuromuscular disease, severe hip/lower limb joint pain, peripheral vascular disease, lower limb amputation)

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Infarction
• Myocardial Infarction

Locations

Country	Name	City	State
United Kingdom	Harefield Hospital	Harefield	Middlesex

Sponsors (2)

Lead Sponsor	Collaborator
Royal Brompton & Harefield NHS Foundation Trust	Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality rate		1 year
Secondary	Occurrence of cardiovascular events		1 and 5 years
Secondary	Need for repeat revascularisation		1 and 5 years
Secondary	Health resource usage		1 and 5 years
Secondary	All-cause mortality		5 years
Secondary	Cardiovascular death		1 and 5 years